Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
JNJ-64251330
DRUG
2 trials
Sponsors
Janssen Research & Development, LLC
Conditions
Adenomatous Polyposis Coli
Healthy
Phase 1
A Study of JNJ-64251330 in Healthy Participants
Completed
NCT04552197
Janssen Research & Development, LLC
Healthy
Start: 2020-09-02
End: 2020-12-29
Updated: 2022-12-02
A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis
Completed
NCT05014360
Janssen Research & Development, LLC
Adenomatous Polyposis Coli
Start: 2021-11-10
End: 2023-02-15
Updated: 2023-06-02
Related Papers
A Phase I, Randomized, Multi‐Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants
Clinical Pharmacology & Therapeutics
2023-12-30
1 citations
Lorpucitinib (JNJ-64251330) in patients with familial adenomatous polyposis (FAP): Results from a phase 1b study.
Journal of Clinical Oncology
2023-06-01
1 citations